Riskpilot← Back to searchSign inGet full accessNORDIC MOLECULE GROUP AS
ASActiveOrg 993355178Kjellandsveien 44, 4373 EgersundManufacture of other food products n.e.c. · NACE 1089Est. 20080 employeeswww.espelandas.no
Revenue 2025
NOK 0
EBITDA margin
—
+11% vs 2024
Equity ratio
43.5%
Financial strength
Net profit 2025
NOK -16K
+98% vs 2024
| Revenue | NOK 0 | — |
| EBITDA | NOK -30K | +11% |
| Net profit | NOK -16K | +98% |
| Total assets | NOK 3,2M | +2% |
| Equity | NOK 1,4M | -1% |
| Employees | 0 | — |
Legal name
NORDIC MOLECULE GROUP AS
Org number
993355178
Legal form
Aksjeselskap
NACE code
1089 · Manufacture of other food products n.e.c.
Founded
26. november 2008
Share capital
NOK 625 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Styrets leder og daglig leder i fellesskap.
Company purpose
Nordic molecule group skal utvikle og drive produksjon av fiskefor, kosttilskudd, biomasse, behandle bioavfall og lage gjødsel. Prosjekter knyttet til bærekraftig energi og teknologi, herunder prosjekter som understøtter overgangen fra dagens fiskefor til bærekraftige løsninger.
Address
Kjellandsveien 44, 4373 Egersund
Website
www.espelandas.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | −0 | −0 | −0 | −0 | −0 |
| EBITDA | −291 | −34 | −21 | −34 | −30 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | −291 | −34 | −21 | −34 | −30 |
| Net financials | −10 | 318 | 349 | −648 | 15 |
| Profit before tax | −300 | 284 | 327 | −682 | −16 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −300 | 284 | 327 | −682 | −16 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 2 773 | 3 297 | 3 703 | 3 133 | 3 188 |
| Equity | 1 474 | 1 758 | 2 086 | 1 403 | 1 388 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 1 298 | 1 539 | 1 617 | 1 729 | 1 800 |
| Total debt | 1 298 | 1 539 | 1 617 | 1 729 | 1 800 |
EBITDA margin
-3044000.0%
This company
15.8%
Market median
-19265923% vs market
20212025
Equity ratio
43.5%
This company
38.2%
Market median
+14% vs market
20212025
Return on equity
-1.1%
This company
18.4%
Market median
-106% vs market
20212025
Net profit margin
-1552100.0%
This company
8.1%
Market median
-19161828% vs market
20212025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20212025
Debt / equity
1.30×
This company
0.62×
Market median
-110% vs market
20212025
- Annual report 2025Filed via Brønnøysundsregistrene · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
ØE Chief Executive Officer | Chief Executive Officer | 2023 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Board of Directors | 2020 | |
| Former (1) | ||
| Chairman | 2020 – 2023 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 50.08% | 50.08% | 2024 | |
| Company | 49.92% | 49.92% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Tommy & Di As
NORDIC MOLECULE GROUP AS Board members of NORDIC MOLECULE GROUP AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Øyvind Espeland | Chief Executive Officer | 0 companies |
| Tommy Nodland | Board of Directors | 0 companies |
| Eivind Tveit Vinningland | Chairman | 0 companies |